首页 > 最新文献

BMC Pharmacology & Toxicology最新文献

英文 中文
Therapeutic drug monitoring of busulfan in pediatric patients: a 5-year observational study. 布苏凡在儿科患者中的治疗药物监测:一项为期5年的观察性研究。
IF 2.7 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2025-10-28 DOI: 10.1186/s40360-025-01015-w
Nedaa Alomari, Amani Kurdi, Meshari Alghamdi, Waleed Alhussaini, Ghanem Ezzeldeen, Eman Alharbi, Alaa Aldahri, Imadul Islam, Mohammed Essa
{"title":"Therapeutic drug monitoring of busulfan in pediatric patients: a 5-year observational study.","authors":"Nedaa Alomari, Amani Kurdi, Meshari Alghamdi, Waleed Alhussaini, Ghanem Ezzeldeen, Eman Alharbi, Alaa Aldahri, Imadul Islam, Mohammed Essa","doi":"10.1186/s40360-025-01015-w","DOIUrl":"10.1186/s40360-025-01015-w","url":null,"abstract":"","PeriodicalId":9023,"journal":{"name":"BMC Pharmacology & Toxicology","volume":"26 1","pages":"175"},"PeriodicalIF":2.7,"publicationDate":"2025-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12570591/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145386912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Combination of B-AP15 and HSP90 inhibitor tanespimycin induces ROS-mediated cytotoxicity in human lung cancer cells. B-AP15和HSP90抑制剂tanespimycin联合诱导ros介导的人肺癌细胞毒性。
IF 2.7 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2025-10-28 DOI: 10.1186/s40360-025-01009-8
Wenying Fu, Hui Lu, Ying Yan, Chongchong Shu, Chenxin Xu, Yinghua Chen, Yiqun Xia, Jundixia Chen, Yunzhi Chen, Peng Zou, Ri Cui, Daoyong Ni
{"title":"Combination of B-AP15 and HSP90 inhibitor tanespimycin induces ROS-mediated cytotoxicity in human lung cancer cells.","authors":"Wenying Fu, Hui Lu, Ying Yan, Chongchong Shu, Chenxin Xu, Yinghua Chen, Yiqun Xia, Jundixia Chen, Yunzhi Chen, Peng Zou, Ri Cui, Daoyong Ni","doi":"10.1186/s40360-025-01009-8","DOIUrl":"10.1186/s40360-025-01009-8","url":null,"abstract":"","PeriodicalId":9023,"journal":{"name":"BMC Pharmacology & Toxicology","volume":"26 1","pages":"177"},"PeriodicalIF":2.7,"publicationDate":"2025-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12570468/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145386931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Identification of potential natural BCL-2 inhibitors for leukemia through an integrated virtual screening approach. 通过综合虚拟筛选方法鉴定白血病潜在的天然BCL-2抑制剂。
IF 2.7 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2025-10-28 DOI: 10.1186/s40360-025-01005-y
Uddalak Das, Arnab Mukherjee, K S Mukunthan, Jitendra Kumar

Leukemia, a hematologic malignancy, frequently involves the overexpression of BCL-2 proteins, contributing to cell survival and apoptosis resistance. Although current BCL-2 inhibitors, including Venetoclax, have shown efficacy, they are limited by adverse side effects and restricted bioavailability. This study employs an integrated computational approach to identify natural BCL-2 inhibitors by screening 407,270 natural compounds. Using ligand- and structure-based virtual screening, we identified two promising compounds, CNP0237679 and CNP0420384, demonstrating strong binding affinities, favorable electronic properties, and stability in dynamic aqueous environments. Both compounds exhibited promising toxicity and pharmacokinetic profiles, indicating the possibility of low toxicity and high bioavailability. They are potential candidates for developing selective BCL-2 inhibitors because of these characteristics. The findings represent a positive step in developing new, naturally derived BCL-2 inhibitors and support additional in vitro and in vivo studies to validate their therapeutic efficacy and safety characteristics.

白血病是一种血液恶性肿瘤,经常涉及BCL-2蛋白的过度表达,有助于细胞存活和细胞凋亡抵抗。尽管目前的BCL-2抑制剂(包括Venetoclax)已显示出疗效,但它们受到不良副作用和生物利用度的限制。本研究通过筛选407,270种天然化合物,采用综合计算方法鉴定天然BCL-2抑制剂。通过基于配体和结构的虚拟筛选,我们发现了两个有前途的化合物CNP0237679和CNP0420384,它们具有很强的结合亲和力、良好的电子性质和在动态水环境中的稳定性。两种化合物均表现出良好的毒性和药代动力学特征,表明其具有低毒性和高生物利用度的可能性。由于这些特性,它们是开发选择性BCL-2抑制剂的潜在候选者。这些发现代表了开发新的天然衍生BCL-2抑制剂的积极一步,并支持更多的体外和体内研究来验证其治疗效果和安全性。
{"title":"Identification of potential natural BCL-2 inhibitors for leukemia through an integrated virtual screening approach.","authors":"Uddalak Das, Arnab Mukherjee, K S Mukunthan, Jitendra Kumar","doi":"10.1186/s40360-025-01005-y","DOIUrl":"10.1186/s40360-025-01005-y","url":null,"abstract":"<p><p>Leukemia, a hematologic malignancy, frequently involves the overexpression of BCL-2 proteins, contributing to cell survival and apoptosis resistance. Although current BCL-2 inhibitors, including Venetoclax, have shown efficacy, they are limited by adverse side effects and restricted bioavailability. This study employs an integrated computational approach to identify natural BCL-2 inhibitors by screening 407,270 natural compounds. Using ligand- and structure-based virtual screening, we identified two promising compounds, CNP0237679 and CNP0420384, demonstrating strong binding affinities, favorable electronic properties, and stability in dynamic aqueous environments. Both compounds exhibited promising toxicity and pharmacokinetic profiles, indicating the possibility of low toxicity and high bioavailability. They are potential candidates for developing selective BCL-2 inhibitors because of these characteristics. The findings represent a positive step in developing new, naturally derived BCL-2 inhibitors and support additional in vitro and in vivo studies to validate their therapeutic efficacy and safety characteristics.</p>","PeriodicalId":9023,"journal":{"name":"BMC Pharmacology & Toxicology","volume":"26 1","pages":"176"},"PeriodicalIF":2.7,"publicationDate":"2025-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12570718/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145386879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hepatic modulation of apelin and galectin-3 by darbepoetin-alpha in Dexamethasone induced insulin-resistant rats. 地塞米松诱导的胰岛素抵抗大鼠肝组织中脂泌素和半乳糖凝集素-3的调节作用。
IF 2.7 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2025-10-27 DOI: 10.1186/s40360-025-01014-x
Halime Tozak Yildiz, Ahmet Turk, Ertan Katirci, Kubra Tugce Kalkan
{"title":"Hepatic modulation of apelin and galectin-3 by darbepoetin-alpha in Dexamethasone induced insulin-resistant rats.","authors":"Halime Tozak Yildiz, Ahmet Turk, Ertan Katirci, Kubra Tugce Kalkan","doi":"10.1186/s40360-025-01014-x","DOIUrl":"10.1186/s40360-025-01014-x","url":null,"abstract":"","PeriodicalId":9023,"journal":{"name":"BMC Pharmacology & Toxicology","volume":"26 1","pages":"173"},"PeriodicalIF":2.7,"publicationDate":"2025-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12560596/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145376121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effects of chronic nicotine administration on behavioral parameters and Na⁺/K⁺-ATPase mRNA expression in the brains of male Swiss Albino mice exposed to chronic stress during adolescence. 慢性尼古丁给药对青春期慢性应激雄性瑞士白化小鼠大脑行为参数和Na + /K + - atp酶mRNA表达的影响。
IF 2.7 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2025-10-27 DOI: 10.1186/s40360-025-01004-z
NourAllah Ahmed, Mohamed Ahmed, Assem Ragab, Mohamed Kamal, Abdullrahman Elsayed, Moustafa Sayed
{"title":"Effects of chronic nicotine administration on behavioral parameters and Na⁺/K⁺-ATPase mRNA expression in the brains of male Swiss Albino mice exposed to chronic stress during adolescence.","authors":"NourAllah Ahmed, Mohamed Ahmed, Assem Ragab, Mohamed Kamal, Abdullrahman Elsayed, Moustafa Sayed","doi":"10.1186/s40360-025-01004-z","DOIUrl":"10.1186/s40360-025-01004-z","url":null,"abstract":"","PeriodicalId":9023,"journal":{"name":"BMC Pharmacology & Toxicology","volume":"26 1","pages":"174"},"PeriodicalIF":2.7,"publicationDate":"2025-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12560373/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145376104","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Concentration-dependent effects of bacterial melanin on new superoxide-producing associates in rat tissues: a rotenone neurotoxic model of parkinson's disease. 细菌黑色素对大鼠组织中新的超氧化物产生关联物的浓度依赖性影响:帕金森病的鱼藤酮神经毒性模型。
IF 2.7 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2025-10-27 DOI: 10.1186/s40360-025-00989-x
Margarita Danielyan, Kristine Karapetyan, Ruzan Simonyan, Gegham Simonyan, Madlena Babayan, Mikhail Poghosyan, Hasmik Yekmalyan, Maxim Simonyan, Karen Simonyan, Kristina Nebogova

Background: Oxidative stress plays a central role in the degeneration of dopaminergic neurons and is a key factor in the pathogenesis of Parkinson's disease (PD). Therefore, antioxidant therapy represents a promising therapeutic strategy. This process involves numerous enzymes and signaling pathways that contribute to disease progression. In the present study, bacterial melanin (BM), known for its high biological activity and biostimulatory effects, was applied as a potential antioxidant. We examined quantitative and qualitative alterations in total fractions of biomembrane-associated components derived from rat tissue in a rotenone-induced PD model, under both low and high BM concentrations, along with an evaluation of their antioxidant properties.

Methods: PD was induced via intracerebral rotenone injection, and the animals were maintained for 4 weeks. BM was administered twice during the survival period at concentrations of 4.5 mg/ml and 9 mg/ml. To confirm disease progression and evaluate potential therapeutic effects of BM, the Rotarod behavioral test was performed following a 4-week survival period. From the biomembranes of brain, lung, and small intestine tissues, superoxide-generating associates were isolated. Their specific amounts (mg/g) and steady-state concentrations of superoxide (O₂⁻) (M) were determined to assess oxidative stress. Antioxidant activity was quantified using the Coomassie Brilliant Blue (CBB) dye decoloration method.

Results: The results demonstrated that BM exerted a membrane-stabilizing effect, with the 9 mg/ml dose proving more effective than 4.5 mg/ml. BM modulated membrane formation across the brain, lung, and small intestine by inhibiting the release of newly formed membrane-bound structures (NLP-Nox associates) and regulating the steady-state concentration of O₂⁻.Behavioral tests further confirmed the effectiveness of BM, with animal behavior parameters in the high-concentration group closely resembling those of the control group. It was found that different BM concentrations possess different antioxidant activity: specific activity at 4.5 mg/ml concentration amounted to 1.2 U/mg, while at 9 mg/ml it was 2.9 U/mg.

Conclusions: The results demonstrate BM's potential as both an antioxidant and membrane-stabilizing agent for PD treatment. The study revealed a concentration-dependent effect of BM's antioxidant activity in the PD model, with 9 mg/mL showing superior efficacy. Further research and clinical trials are warranted to validate its therapeutic efficacy.

Clinical trial number: Not applicable.

背景:氧化应激在多巴胺能神经元变性中起核心作用,是帕金森病(PD)发病的关键因素。因此,抗氧化治疗是一种很有前途的治疗策略。这一过程涉及许多促进疾病进展的酶和信号通路。在本研究中,细菌黑色素(BM)以其高生物活性和生物刺激作用而闻名,被用作潜在的抗氧化剂。在鱼藤酮诱导的PD模型中,我们检测了来自大鼠组织的生物膜相关成分在低浓度和高浓度下的定量和定性变化,并评估了它们的抗氧化性能。方法:采用鱼藤酮脑内注射诱导PD,维持4周。在存活期间,以4.5 mg/ml和9 mg/ml的浓度给药两次。为了确认疾病进展并评估BM的潜在治疗效果,在4周生存期后进行Rotarod行为测试。从脑、肺和小肠组织的生物膜中分离出产生超氧化物的伴生物。他们的特定量(mg/g)和超氧(O₂)(M)的稳态浓度被测定来评估氧化应激。采用考马斯亮蓝(CBB)染料脱色法测定抗氧化活性。结果:BM具有稳定膜的作用,9mg /ml比4.5 mg/ml更有效。BM通过抑制新形成的膜结合结构(NLP-Nox相关物)的释放和调节O₂的稳态浓度来调节脑、肺和小肠的膜形成。行为学实验进一步证实了BM的有效性,高浓度组的动物行为参数与对照组非常接近。结果表明,不同浓度的BM具有不同的抗氧化活性,4.5 mg/ml浓度下的比活性为1.2 U/mg, 9 mg/ml浓度下的比活性为2.9 U/mg。结论:结果表明BM作为PD治疗的抗氧化剂和膜稳定剂的潜力。本研究发现,BM在PD模型中的抗氧化活性呈浓度依赖性,以9 mg/mL的效果较好。需要进一步的研究和临床试验来验证其治疗效果。临床试验号:不适用。
{"title":"Concentration-dependent effects of bacterial melanin on new superoxide-producing associates in rat tissues: a rotenone neurotoxic model of parkinson's disease.","authors":"Margarita Danielyan, Kristine Karapetyan, Ruzan Simonyan, Gegham Simonyan, Madlena Babayan, Mikhail Poghosyan, Hasmik Yekmalyan, Maxim Simonyan, Karen Simonyan, Kristina Nebogova","doi":"10.1186/s40360-025-00989-x","DOIUrl":"10.1186/s40360-025-00989-x","url":null,"abstract":"<p><strong>Background: </strong>Oxidative stress plays a central role in the degeneration of dopaminergic neurons and is a key factor in the pathogenesis of Parkinson's disease (PD). Therefore, antioxidant therapy represents a promising therapeutic strategy. This process involves numerous enzymes and signaling pathways that contribute to disease progression. In the present study, bacterial melanin (BM), known for its high biological activity and biostimulatory effects, was applied as a potential antioxidant. We examined quantitative and qualitative alterations in total fractions of biomembrane-associated components derived from rat tissue in a rotenone-induced PD model, under both low and high BM concentrations, along with an evaluation of their antioxidant properties.</p><p><strong>Methods: </strong>PD was induced via intracerebral rotenone injection, and the animals were maintained for 4 weeks. BM was administered twice during the survival period at concentrations of 4.5 mg/ml and 9 mg/ml. To confirm disease progression and evaluate potential therapeutic effects of BM, the Rotarod behavioral test was performed following a 4-week survival period. From the biomembranes of brain, lung, and small intestine tissues, superoxide-generating associates were isolated. Their specific amounts (mg/g) and steady-state concentrations of superoxide (O₂⁻) (M) were determined to assess oxidative stress. Antioxidant activity was quantified using the Coomassie Brilliant Blue (CBB) dye decoloration method.</p><p><strong>Results: </strong>The results demonstrated that BM exerted a membrane-stabilizing effect, with the 9 mg/ml dose proving more effective than 4.5 mg/ml. BM modulated membrane formation across the brain, lung, and small intestine by inhibiting the release of newly formed membrane-bound structures (NLP-Nox associates) and regulating the steady-state concentration of O₂⁻.Behavioral tests further confirmed the effectiveness of BM, with animal behavior parameters in the high-concentration group closely resembling those of the control group. It was found that different BM concentrations possess different antioxidant activity: specific activity at 4.5 mg/ml concentration amounted to 1.2 U/mg, while at 9 mg/ml it was 2.9 U/mg.</p><p><strong>Conclusions: </strong>The results demonstrate BM's potential as both an antioxidant and membrane-stabilizing agent for PD treatment. The study revealed a concentration-dependent effect of BM's antioxidant activity in the PD model, with 9 mg/mL showing superior efficacy. Further research and clinical trials are warranted to validate its therapeutic efficacy.</p><p><strong>Clinical trial number: </strong>Not applicable.</p>","PeriodicalId":9023,"journal":{"name":"BMC Pharmacology & Toxicology","volume":"26 1","pages":"172"},"PeriodicalIF":2.7,"publicationDate":"2025-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12557932/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145376165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Green synthesis, characterization and antibacterial potential of zinc oxide nanoparticles with naringenin. 柚皮素氧化锌纳米颗粒的绿色合成、表征及抗菌潜力。
IF 2.7 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2025-10-24 DOI: 10.1186/s40360-025-00974-4
Leirika Ngangom, Kunal Sharma, Neha Pandey, Shabaaz Begum Jp, Divya Venugopal
{"title":"Green synthesis, characterization and antibacterial potential of zinc oxide nanoparticles with naringenin.","authors":"Leirika Ngangom, Kunal Sharma, Neha Pandey, Shabaaz Begum Jp, Divya Venugopal","doi":"10.1186/s40360-025-00974-4","DOIUrl":"10.1186/s40360-025-00974-4","url":null,"abstract":"","PeriodicalId":9023,"journal":{"name":"BMC Pharmacology & Toxicology","volume":"26 1","pages":"170"},"PeriodicalIF":2.7,"publicationDate":"2025-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12551134/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145367373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ultrasound stimulated microbubble cavitation promoted the anticancer effect of Lenvatinib on anaplastic thyroid cancer. 超声刺激微泡空化可促进Lenvatinib对间变性甲状腺癌的抗癌作用。
IF 2.7 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2025-10-24 DOI: 10.1186/s40360-025-00995-z
Sujuan Li, Rongling Zhong, Anping Zhang, Jiaxin Li, Jie Song, Wenbo Ding, Zhijun Fang

Background: Anaplastic thyroid cancer (ATC) is an extremely aggressive subtype of thyroid cancer associated with poor prognosis. Thus, the necessity to develop innovative treatment approaches is critical. Lenvatinib is the one of the drugs approved for ATC in clinic, however, its efficacy is limited. The present study investigated the combined effect of ultrasound stimulated microbubble cavitation (USMC) and Lenvatinib on tumor growth.

Methods: Undifferentiated thyroid carcinoma C643 cells were subcutaneously inoculated into mice to establish transplanted tumor model and mice were allocated into 4 groups (model group, Lenvatinib group, USMC group, and Lenvatinib + USMC group). Blood perfusion in tumors was estimated with contrast-enhanced ultrasound (CEUS) and the microvascular structures were observed by transmission electron microscopy. H&E and Masson staining was applied. Immunohistochemical staining for CD31, Ki67, Caspase 3 expression, ELISA for VEGFA, NO, and PGF2 levels, western blot for HIF-1α and Akt/PI3K proteins, and immunofluorescence for VEGFA and ICAM-1.

Results: USMC caused mild enlargement and congestion of tumor microvessels. Moreover, upon exposure to USMC, the area under the curve and peak intensity of CEUS (MI = 0.4) showed an increase, indicating that USMC has the potential to augment blood flow within tumors. The combination of USMC and Lenvatinib meaningfully suppressed tumor growth, induced apoptosis, inhibited Ki67 expression and extended the survival of mice bearing C643 tumor. USMC also improved the anti-angiogenesis effect of Lenvatinib, as demonstrated by decreased expression of collagen fiber, CD31, HIF-1α and VEGFA in tumors and inactivation of PI3K/Akt pathway. Increment in ICAM-1, PGF2 and NO expression was also observed in the combination group.

Conclusions: These results indicated that the combination of Lenvatinib and USMC could serve as a promising and innovative method for ATC therapy, surpassing the effectiveness of Lenvatinib monotherapy.

背景:间变性甲状腺癌(ATC)是一种极具侵袭性的甲状腺癌亚型,预后较差。因此,开发创新治疗方法的必要性至关重要。Lenvatinib是临床批准用于ATC的药物之一,但其疗效有限。本研究探讨超声刺激微泡空化(USMC)联合Lenvatinib对肿瘤生长的影响。方法:小鼠皮下接种未分化甲状腺癌C643细胞建立移植瘤模型,将小鼠分为模型组、Lenvatinib组、USMC组、Lenvatinib + USMC组。对比增强超声(CEUS)评估肿瘤血流灌注,透射电镜观察微血管结构。H&E和Masson染色。免疫组化染色检测CD31、Ki67、Caspase 3表达,ELISA检测VEGFA、NO和PGF2水平,western blot检测HIF-1α和Akt/PI3K蛋白,免疫荧光检测VEGFA和ICAM-1。结果:USMC引起肿瘤微血管轻度肿大和充血。此外,暴露于USMC后,超声造影曲线下面积和峰值强度(MI = 0.4)均增加,表明USMC具有增加肿瘤内血流的潜力。USMC联合Lenvatinib可显著抑制肿瘤生长,诱导细胞凋亡,抑制Ki67表达,延长C643肿瘤小鼠的生存期。USMC还增强了Lenvatinib的抗血管生成作用,其表现为肿瘤中胶原纤维、CD31、HIF-1α和VEGFA的表达降低,PI3K/Akt通路失活。联合用药组ICAM-1、PGF2、NO表达增加。结论:Lenvatinib与USMC联合治疗ATC是一种很有前景的创新方法,其疗效超过Lenvatinib单药治疗。
{"title":"Ultrasound stimulated microbubble cavitation promoted the anticancer effect of Lenvatinib on anaplastic thyroid cancer.","authors":"Sujuan Li, Rongling Zhong, Anping Zhang, Jiaxin Li, Jie Song, Wenbo Ding, Zhijun Fang","doi":"10.1186/s40360-025-00995-z","DOIUrl":"10.1186/s40360-025-00995-z","url":null,"abstract":"<p><strong>Background: </strong>Anaplastic thyroid cancer (ATC) is an extremely aggressive subtype of thyroid cancer associated with poor prognosis. Thus, the necessity to develop innovative treatment approaches is critical. Lenvatinib is the one of the drugs approved for ATC in clinic, however, its efficacy is limited. The present study investigated the combined effect of ultrasound stimulated microbubble cavitation (USMC) and Lenvatinib on tumor growth.</p><p><strong>Methods: </strong>Undifferentiated thyroid carcinoma C643 cells were subcutaneously inoculated into mice to establish transplanted tumor model and mice were allocated into 4 groups (model group, Lenvatinib group, USMC group, and Lenvatinib + USMC group). Blood perfusion in tumors was estimated with contrast-enhanced ultrasound (CEUS) and the microvascular structures were observed by transmission electron microscopy. H&E and Masson staining was applied. Immunohistochemical staining for CD31, Ki67, Caspase 3 expression, ELISA for VEGFA, NO, and PGF2 levels, western blot for HIF-1α and Akt/PI3K proteins, and immunofluorescence for VEGFA and ICAM-1.</p><p><strong>Results: </strong>USMC caused mild enlargement and congestion of tumor microvessels. Moreover, upon exposure to USMC, the area under the curve and peak intensity of CEUS (MI = 0.4) showed an increase, indicating that USMC has the potential to augment blood flow within tumors. The combination of USMC and Lenvatinib meaningfully suppressed tumor growth, induced apoptosis, inhibited Ki67 expression and extended the survival of mice bearing C643 tumor. USMC also improved the anti-angiogenesis effect of Lenvatinib, as demonstrated by decreased expression of collagen fiber, CD31, HIF-1α and VEGFA in tumors and inactivation of PI3K/Akt pathway. Increment in ICAM-1, PGF<sub>2</sub> and NO expression was also observed in the combination group.</p><p><strong>Conclusions: </strong>These results indicated that the combination of Lenvatinib and USMC could serve as a promising and innovative method for ATC therapy, surpassing the effectiveness of Lenvatinib monotherapy.</p>","PeriodicalId":9023,"journal":{"name":"BMC Pharmacology & Toxicology","volume":"26 1","pages":"171"},"PeriodicalIF":2.7,"publicationDate":"2025-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12551152/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145367460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Quality evaluation of cephalexin, cefuroxime, and ceftriaxone medicines marketed in Addis Ababa city, Ethiopia with three tier level approach and anti-microbial assays. 在埃塞俄比亚亚的斯亚贝巴市销售的头孢氨苄、头孢呋辛和头孢曲松药物的质量评价,采用三级方法和抗微生物测定。
IF 2.7 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2025-10-24 DOI: 10.1186/s40360-025-01018-7
Worku Birhane, Tigist Getachew, Molalegne Bitew, Mequanint Mitiku, Tibebu Abera, Tadele Eticha, Ayenew Ashenef

Background: The prevalence of substandard and falsified (SF) medicines hinders progresses towards sustainable development goals in providing quality health care. It is posed as major public health threat. Cephalosporin are beta-lactam antibiotics used for treating penicillin resistant infections and are widely prescribed. Three tiered level approach is a quality assessment methodology that consists of visual and physical inspection of labelling, packaging, and inserts of the dosage form and then performing rapid screening and finally carrying out full pharmacopoeial tests.

Objectives: It is aimed at assessing the quality of three cephalosporin medicines marketed in Addis Ababa city, Ethiopia.

Methods: Different cephalosporin products for post market quality survey were collected from different health care systems in Addis Ababa, Ethiopia. Purposive sampling was employed for sample collection using the WHO and National Regulatory Authority (NRA) guidelines. A total of 56 samples (13 cefuroxime axetil tablets, 21 cephalexin capsules, and 22 samples of ceftriaxone powder for injections) were collected. All samples had been subjected to visual inspection, then screening test with GPHF-minilab™ protocol, and later confirmatory physicochemical tests per U.S. Pharmacopoeia monograph (USP 44-NF39) methods. Finally, antimicrobial effectiveness tests were carried out.

Results: All samples had passed visual inspections and screening test with GPHF-minilab™. Twenty-four samples were subjected for further confirmatory tests. All samples complied for the dissolution and assay tests with USP 44-NF39 specifications. However, two samples, each from cephalexin capsule and ceftriaxone powder for injection failed to meet the uniformity of dosage units' test. Cephalexin capsule and cefuroxime axetil tablets were found to be more active against S. aureus (with zone of inhibition (Z.O.I.) as 28.7 mm and 32.1 mm, respectively), while ceftriaxone was found to be most effective against P. mirabilis (Z.O.I. as 33.39 mm). For antimicrobial assays, 24 (samples) multiplied by 5 (microorganism types) with total amount of 120 antibiograms were generated. Eighty-five (85) were found to be sensitive, 15 intermediate and 20 resistants.

Conclusion: The tested medicinal products were of good quality. However, there are differences in the antimicrobial activity effectiveness results against tested bacterial strains. It implies that resistance to Cephalosprins' is emerging in the study area.

背景:伪劣药品的普遍存在阻碍了在提供高质量卫生保健方面实现可持续发展目标的进展。它被视为主要的公共卫生威胁。头孢菌素是用于治疗青霉素耐药感染的β -内酰胺类抗生素,被广泛开处方。三级方法是一种质量评估方法,包括对剂型的标签、包装和说明书进行目视和实物检查,然后进行快速筛选,最后进行完整的药典试验。目的:评估在埃塞俄比亚亚的斯亚贝巴市销售的三种头孢菌素类药物的质量。方法:从埃塞俄比亚亚的斯亚贝巴不同卫生保健系统收集不同头孢菌素产品进行上市后质量调查。根据世卫组织和国家监管机构(NRA)的指导方针,采用有目的抽样进行样本收集。共采集56份样品(头孢呋辛酯片13份,头孢氨苄胶囊21份,注射用头孢曲松粉剂22份)。所有样品都经过目视检查,然后使用GPHF-minilab™方案进行筛选试验,然后根据美国药典各论(USP 44-NF39)方法进行验证性理化试验。最后进行抗菌效果试验。结果:所有样品均通过GPHF-minilab™的目视检查和筛选试验。24个样本进行了进一步的确认试验。所有样品均符合USP 44-NF39规范的溶解和测定试验。但注射用头孢氨苄胶囊和头孢曲松粉剂两种样品均不符合剂量单位检测的均匀性。头孢氨苄胶囊和头孢呋辛酯片对金黄色葡萄球菌的抑菌效果较好(抑菌带分别为28.7 mm和32.1 mm),头孢曲松对奇异假单胞菌的抑菌带效果最好(抑菌带为33.39 mm)。抗菌试验用24份(样品)乘以5种(微生物种类),总用量为120抗生素克。85株为敏感菌株,15株为中间菌株,20株为耐药菌株。结论:所检药品质量良好。然而,对所测菌株的抑菌活性效果结果存在差异。这意味着对头孢菌素的耐药性正在研究地区出现。
{"title":"Quality evaluation of cephalexin, cefuroxime, and ceftriaxone medicines marketed in Addis Ababa city, Ethiopia with three tier level approach and anti-microbial assays.","authors":"Worku Birhane, Tigist Getachew, Molalegne Bitew, Mequanint Mitiku, Tibebu Abera, Tadele Eticha, Ayenew Ashenef","doi":"10.1186/s40360-025-01018-7","DOIUrl":"10.1186/s40360-025-01018-7","url":null,"abstract":"<p><strong>Background: </strong>The prevalence of substandard and falsified (SF) medicines hinders progresses towards sustainable development goals in providing quality health care. It is posed as major public health threat. Cephalosporin are beta-lactam antibiotics used for treating penicillin resistant infections and are widely prescribed. Three tiered level approach is a quality assessment methodology that consists of visual and physical inspection of labelling, packaging, and inserts of the dosage form and then performing rapid screening and finally carrying out full pharmacopoeial tests.</p><p><strong>Objectives: </strong>It is aimed at assessing the quality of three cephalosporin medicines marketed in Addis Ababa city, Ethiopia.</p><p><strong>Methods: </strong>Different cephalosporin products for post market quality survey were collected from different health care systems in Addis Ababa, Ethiopia. Purposive sampling was employed for sample collection using the WHO and National Regulatory Authority (NRA) guidelines. A total of 56 samples (13 cefuroxime axetil tablets, 21 cephalexin capsules, and 22 samples of ceftriaxone powder for injections) were collected. All samples had been subjected to visual inspection, then screening test with GPHF-minilab™ protocol, and later confirmatory physicochemical tests per U.S. Pharmacopoeia monograph (USP 44-NF39) methods. Finally, antimicrobial effectiveness tests were carried out.</p><p><strong>Results: </strong>All samples had passed visual inspections and screening test with GPHF-minilab™. Twenty-four samples were subjected for further confirmatory tests. All samples complied for the dissolution and assay tests with USP 44-NF39 specifications. However, two samples, each from cephalexin capsule and ceftriaxone powder for injection failed to meet the uniformity of dosage units' test. Cephalexin capsule and cefuroxime axetil tablets were found to be more active against S. aureus (with zone of inhibition (Z.O.I.) as 28.7 mm and 32.1 mm, respectively), while ceftriaxone was found to be most effective against P. mirabilis (Z.O.I. as 33.39 mm). For antimicrobial assays, 24 (samples) multiplied by 5 (microorganism types) with total amount of 120 antibiograms were generated. Eighty-five (85) were found to be sensitive, 15 intermediate and 20 resistants.</p><p><strong>Conclusion: </strong>The tested medicinal products were of good quality. However, there are differences in the antimicrobial activity effectiveness results against tested bacterial strains. It implies that resistance to Cephalosprins' is emerging in the study area.</p>","PeriodicalId":9023,"journal":{"name":"BMC Pharmacology & Toxicology","volume":"26 1","pages":"169"},"PeriodicalIF":2.7,"publicationDate":"2025-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12551207/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145367379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Identification of novel dihydroorotate dehydrogenase (DHODH) inhibitors for cancer: computational drug repurposing strategy. 新型癌症二氢酸脱氢酶(DHODH)抑制剂的鉴定:计算药物再利用策略。
IF 2.7 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2025-10-22 DOI: 10.1186/s40360-025-01007-w
Rahamathtunnisa Rajamohamed, Shanthi Veerappapillai
{"title":"Identification of novel dihydroorotate dehydrogenase (DHODH) inhibitors for cancer: computational drug repurposing strategy.","authors":"Rahamathtunnisa Rajamohamed, Shanthi Veerappapillai","doi":"10.1186/s40360-025-01007-w","DOIUrl":"10.1186/s40360-025-01007-w","url":null,"abstract":"","PeriodicalId":9023,"journal":{"name":"BMC Pharmacology & Toxicology","volume":"26 1","pages":"168"},"PeriodicalIF":2.7,"publicationDate":"2025-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12542235/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145343136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
BMC Pharmacology & Toxicology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1